BC
HRTX icon

Broadfin Capital’s Heron Therapeutics HRTX Stock Holding History

Broadfin Capital’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$2.11M Sell
89,730
-8,507
-9% -$188K 0.28% 38
2019
Q3 		$1.82M Sell
98,237
-559,761
-85% -$10.3M 0.34% 40
2019
Q2 		$12.2M Buy
657,998
+450,000
+216% +$8.99M 2.66% 14
2019
Q1 		$5.08M Buy
207,998
+88,704
+74% +$2.32M 1.05% 32
2018
Q4 		$3.09M Sell
119,294
-171,919
-59% -$4.73M 0.41% 43
2018
Q3 		$9.22M Sell
291,213
-228,574
-44% -$8.51M 1.36% 25
2018
Q2 		$20.2M Sell
519,787
-1,061,629
-67% -$33.8M 3.18% 11
2018
Q1 		$43.6M Sell
1,581,416
-447,102
-22% -$10.1M 6.8% 3
2017
Q4 		$36.7M Sell
2,028,518
-1,427,192
-41% -$23.3M 6% 3
2017
Q3 		$55.8M Sell
3,455,710
-962,649
-22% -$15.1M 8.26% 1
2017
Q2 		$61.2M Sell
4,418,359
-529,044
-11% -$7.66M 7.43% 2
2017
Q1 		$74.2M Buy
4,947,403
+1,047,816
+27% +$14.5M 8.99% 2
2016
Q4 		$51.1M Buy
3,899,587
+1,049,587
+37% +$16.5M 5.67% 4
2016
Q3 		$49.1M Buy
2,850,000
+1,599,896
+128% +$29.7M 4.4% 7
2016
Q2 		$22.6M Sell
1,250,104
-215,371
-15% -$4.2M 2.19% 11
2016
Q1 		$27.8M Sell
1,465,475
-766,526
-34% -$15.1M 2.69% 10
2015
Q4 		$59.6M Buy
2,232,001
+370,000
+20% +$9.89M 3.67% 6
2015
Q3 		$45.4M Sell
1,862,001
-534,680
-22% -$17.8M 2.53% 9
2015
Q2 		$74.7M Sell
2,396,681
-411,492
-15% -$7.74M 4.01% 4
2015
Q1 		$40.9M Hold
2,808,173
– – 3.18% 8
2014
Q4 		$28.3M Hold
2,808,173
– – 2.46% 11
2014
Q3 		$23.4M Hold
2,808,173
– – 2.45% 11
2014
Q2 		$34.6M Buy
2,808,173
+575,000
+26% +$6.87M 3.37% 7
2014
Q1 		$31.1M Buy
+2,233,173
New +$29.8M 3.01% 7

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Broadfin Capital's HRTX Position: Q4 2019 in Review

Broadfin Capital reduced its Heron Therapeutics (HRTX) stake by 8.7% in Q4 2019, selling an estimated $188K and leaving 89,730 shares worth $2.11M. The position accounts for 0.28% of the portfolio, ranked #38.

Broadfin Capital first reported a position in HRTX in Q1 2014 and has held it in 24 quarters since. The position peaked at $74.7M in Q2 2015. 199 funds tracked by Wall St. Rank hold HRTX as of Q4 2019.

  • Broadfin Capital held 89,730 shares of Heron Therapeutics worth $2.11M as of Q4 2019.
  • Broadfin Capital sold 8,507 Heron Therapeutics shares in Q4 2019, an estimated $188K.
  • Heron Therapeutics made up 0.28% of Broadfin Capital's portfolio in Q4 2019, its #38 holding.
  • Broadfin Capital first reported a position in Heron Therapeutics in Q1 2014 and has held it in 24 quarters since.
  • Broadfin Capital's Heron Therapeutics position peaked at $74.7M in Q2 2015.
  • 199 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.